Since Hsp90 is central to the heme maturation of iNOS, sGC and globin, its well defined role in cancer progression needs to be critically looked at cautiously with a fresh perspective so as to overcome potential deleterious effects of various Hsp90 inhibitors for better therapeutic intervention. The gene discussed is NOS2; the disease is cancer.